Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1926 1
1927 1
1936 1
1945 2
1946 16
1947 9
1948 7
1949 3
1950 7
1951 6
1952 6
1953 6
1954 5
1955 5
1956 13
1957 5
1958 4
1959 9
1960 5
1961 6
1962 10
1963 8
1964 10
1965 13
1966 7
1967 3
1968 12
1969 8
1970 8
1971 10
1972 7
1973 18
1974 20
1975 19
1976 13
1977 16
1978 15
1979 18
1980 25
1981 38
1982 39
1983 45
1984 48
1985 53
1986 59
1987 60
1988 67
1989 75
1990 67
1991 62
1992 93
1993 84
1994 100
1995 118
1996 142
1997 123
1998 125
1999 157
2000 156
2001 162
2002 198
2003 215
2004 257
2005 355
2006 412
2007 489
2008 496
2009 570
2010 727
2011 868
2012 954
2013 1083
2014 1222
2015 1359
2016 1445
2017 1509
2018 1760
2019 1981
2020 2341
2021 2688
2022 3157
2023 3154
2024 3492
2025 1906
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,347 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic engineering to facilitate anti-tumor immunity.
Schild T, Wallisch P, Zhao Y, Wang YT, Haughton L, Chirayil R, Pierpont K, Chen K, Nunes-Violante S, Cross J, de Stanchina E, Thompson CB, Scheinberg DA, Perry JSA, Keshari KR. Schild T, et al. Among authors: chen k. Cancer Cell. 2025 Mar 10;43(3):552-562.e9. doi: 10.1016/j.ccell.2025.02.004. Epub 2025 Feb 27. Cancer Cell. 2025. PMID: 40020672
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M. Awad MM, et al. Among authors: chen kn. J Clin Oncol. 2025 Apr 20;43(12):1453-1462. doi: 10.1200/JCO-24-02239. Epub 2025 Jan 8. J Clin Oncol. 2025. PMID: 39778121 Free PMC article. Clinical Trial.
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.
Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, Zhang M, Zhang J, Wang W, Cao B, Jin Y, Sun M, Lin Y, Luo S, Li Z, Yang L, Ke Y, Yu H, Li J, Wang Q, Zhu J, Wang F, Xu RH. Wang ZX, et al. Among authors: chen k. Med. 2024 Sep 13;5(9):1150-1163.e3. doi: 10.1016/j.medj.2024.05.009. Epub 2024 Jun 12. Med. 2024. PMID: 38870931 Clinical Trial.
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N; CheckMate 816 Investigators. Forde PM, et al. Among authors: chen kn. N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931. Online ahead of print. N Engl J Med. 2025. PMID: 40454642
31,347 results
You have reached the last available page of results. Please see the User Guide for more information.